Objective: In Mexico, obesity is the main public health concern and obesity-related conditions represent a very high costs for the Mexican public health system. Liraglutide 3mg is associated with significant and sustained weight loss and improves related complications. The objective of this study is to determine the cost-effectiveness of Liraglutide 3.0mg vs orlistat and no-treatment in Mexico.

Methods: A cost-effectiveness analysis was conducted by means of a Discrete Event Simulation model, which emulates different health states that cover the possible complications associated with obesity, such health states are dependent on the weight loss achieved and therefore have a substantial impact on health care resources and costs. The costs are presented in USD. The population aimed is adults from 18-60 years old with initial BMI≥35 and at least 2 complications onset. This study was conducted from the Mexican institutional perspective. Outcomes measure costs and complications years avoided. A probabilistic sensitivity analysis (first order Monte Carlo Simulation, 1,000 interactions) was developing to assess the robustness of the case base results.

Results: Liraglutide 3.0 mg is associated to less cost when compared to orlistat and no-treatment ($177,503 vs $18,146 and $192,382 respectively) and it leads to savings ($4,642.82 compared to orlistat and $14,878.97 no-treatment). The efficacy results shows that Liraglutide 3.0 mg are associated to less years with complications (17.6 vs 19.02 and 22.3). The cost-effectiveness base case analysis indicates that Liraglutide 3.0mg is a dominant alternative (more effectiveness, less cost). The results of the probabilistic sensitivity analysis showed to be consistent to the base case analysis. Liraglutide 3.0mg is a dominant alternative.

Conclusions: Obesity imposes a large economic burden. In patients from 18-60 years old with initial BMI≥35 and at least 2 complications onset, Liraglutide 3.0mg shows important benefits regarding obesity complications avoided that generate important savings for the Mexican public sector.